What We're Reading: Page 259
Industry reads hand-picked by our editors
Nov 14, 2018
-
Stat
Extraordinary tactics, perverse incentives: Makers of top-selling drugs hike prices in lockstep, and patients bear the cost
-
Bloomberg
SoftBank-backed biotech Roivant climbs to $7 billion valuation
-
CNBC
Tweet leads Mark Cuban to invest in biotech company Perlara and quest to cure rare genetic disease
-
The New York Times
20 Americans die each day waiting for organs. Can pigs save them?
Nov 13, 2018
Nov 12, 2018
-
Los Angeles Times
With better drugs for high cholesterol, doctors become more ambitious with their treatment goals
-
Chemical & Engineering News
Have antisense oligonucleotides hit their stride?
-
The New York Times
Dementia is getting some very public faces
-
CNBC
The inside story of Quanttus, a failed health tech start-up whose alums are now health leaders at Apple, Amazon, Alphabet and other giants
Nov 09, 2018
Nov 08, 2018
Nov 07, 2018
-
Stat
Indicted for biotech insider trading, Rep. Chris Collins keeps his seat
-
The Wall Street Journal
CVS lays out vision for future as Aetna merger looms
-
The Philadelphia Inquirer
The cancer-preventing HPV vaccine a dozen years on: Progress, fear, and loathing
Nov 06, 2018
-
Reuters
Takeda CEO confident of investor backing for $62 billion Shire deal
-
The New York Times
Cancer society executive resigns amid upset over corporate partnerships
-
The Wall Street Journal
Insys looks to sell opioid-related assets, including Subsys
-
Wired
How antivax PACs helped shape midterm ballots
Previous
